Type:2 Ampoules
Generic Name:Hydroxyprogesterone Caproate
Manufacturer:Popular Pharmaceuticals Ltd.
Price:৳800.00
Preterm Labor, Recurrent miscarriage, Amenorrhoea, Abnormal uterine bleeding, Palliative treatment of advanced, inoperable endometrial carcinoma
IM Administration Inject IM over 1 minute in upper outer quadrant of the gluteus maximus Inject IM over 1 minute in upper outer quadrant of the gluteus maximus The solution if viscous and oilyThe solution if viscous and oily 1-mL vial does not contain preservatives and is for single dose use Once opened, the 5-mL multidose vial must be used within 5 weeks
Intramuscular Preterm Labor Indicated for prevention of preterm labor in a singleton pregnancy for patients aged 16 years or older who have a history of spontaneous preterm birth 250 mg IM qWeek Initiate between the 16th and 20th week of gestation and ending at the 37th week of gestation or birth (whichever is first) Recurrent miscarriage Adult: 250-500 mg wkly during the 1st half of pregnancy. Amenorrhoea; Abnormal uterine bleeding Adult: Single dose of 375 mg; may repeat at 4-wkly intervals if needed. After 4 days of desquamation, or if there is no bleeding within 21 days after admin of the drug, may initiate cyclic therapy that includes an oestrogen. For cyclic treatment (28-day cycle): Administer 20 mg of estradiol valerate on day 1, and on day 15, administer 250 mg of hydroxyprogesterone caproate and 5 mg of estradiol valerate. May repeat cyclic therapy at 4-wkly intervals as needed. Palliative treatment of advanced, inoperable endometrial carcinoma Adult: Usual dose: ?1 g, may repeat once or more times wkly. Usual range: 1-7 g/wk. Discontinue treatment if relapse occurs or if the objective response is not achieved after 12 wk of treatment. Hepatic Impairment Not studied; product is extensively metabolized in liver; potential for reduce elimination
Safety and efficacy not established
Not studied in patients with renal impairment
Undiagnosed vaginal bleeding, breast cancer, pregnancy, lactation. Thrombophlebitis, thromboembolic disorders, cerebral apoplexy or a history of these conditions. Markedly impaired liver function.
Hydroxyprogesterone caproate stimulates luteal actions, changes in uterus and vagina as seen in early pregnancy. It also has prolonged uterotrophic effect. Contractile response of the myometrium to oxytocin is inhibited.
Physical examination is advised prior to starting therapy. Hepatic impairment, mental depression. Monitor blood glucose in diabetic patients. Discontinue treatment upon signs of thromboembolic and thrombotic disorders. Discontinue treatment if unexplained, sudden or gradual, partial or complete loss of vision, protopsis, diplopia or papilledema, retinal vascular lesions or migraine occur. Caution when used in patients with conditions that might be worsened by fluid retention (e.g. asthma, seizure disorders, migraine, cardiac or renal dysfunction).
No adequate or well-controlled studies in women during first trimester
Increased clearance when used with enzyme inducers e.g. carbamazepine and phenytoin. May inhibit metabolism of ciclosporin.
HPC DS InjectionPrice: ৳750.00
Popular Pharmaceuticals Ltd.
